The fixed-bearing Infinity implant (Wright Medical Group) for total ankle arthroplasty (TAA) was introduced to the U.K. market in 2014 and has rapidly become the most commonly used TAA implant. This is a follow-up report of a multicenter, non-designer, prospective observational study of 503 Infinity fixed-bearing TAA implants. The average follow-up of patients in the current report was 44.9 months (range, 28.3 to 63.9 months). The primary aim was to assess survivorship, complications, and reoperations. Secondary aims were to assess radiographic outcomes and patient-reported outcome measures (PROMs) and the influence of patient factors at 2 years. Four hundred and sixty-nine implants were evaluated at 2-year follow-up. Fifteen patients died, 8 withdrew, and 3 were lost to follow-up. The 2-year survivorship was 98.8%, and the non-revision reoperation rate was 2.8%. There was a significant improvement across all functional outcome scores from baseline to 2 years. The early experience and small rate of adverse events reported in this study continue to support the use of the Infinity TAA implant for the treatment of end-stage ankle arthritis.
Level of Evidence:
Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.